Andrew Huberman· PhD
So, we treated Michael as the first patient ever, that we're aware of, with a PD-1 inhibitor, and he responded so incredibly well.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So, we treated Michael as the first patient ever, that we're aware of, with a PD-1 inhibitor, and he responded so incredibly well.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
Turns out it works in about 18% of patients. So, it was a uniformly fatal cancer within one year. Now, about 20% of people will live beyond a year, and it can be really transformative. So, it changed clinical practice for angiosarcoma.
Turns out it works in about 18% of patients. So, it was a uniformly fatal cancer within one year. Now, about 20% of people will live beyond a year, and it can be really transformative. So, it changed clinical practice for angiosarcoma.